Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-25-000262
Filing Date
2025-08-05
Accepted
2025-08-05 13:35:05
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10776
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 4393
  Complete submission text file 0000902219-25-000262.txt   17323
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Subject) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94122 | Film No.: 251184096
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)